Parkinson's Disease: The Role of Dopamine AgonistsA. Lieberman, X. Lataste |
From inside the book
20 pages matching advanced Parkinson's disease in this book
Where's the rest of this book?
Results 1-3 of 20
Contents
Series editors foreword | 7 |
an update on the mode of action | 13 |
Early dopamine agonist treatment in Parkinsons disease | 29 |
Copyright | |
3 other sections not shown
Other editions - View all
Common terms and phrases
abnormal involuntary movements adenylate cyclase advanced disease advanced Parkinson's disease adverse effects adverse reactions Amantadine antiparkinsonian bradykinesia bromocrip bromocriptine and levodopa Bromocriptine group bromocriptine in Parkinson's Calne carbidopa chronic clozapine combination with levodopa combined therapy decreased deprenyl Developments in Parkinson's diurnal response fluctuations dopamine agonists dopamine receptors dopaminergic dopaminergic agonists dose of levodopa doses of bromocriptine double-blind drug dyskinesias dystonia early combination effects of bromocriptine efficacy ergoline evaluated Fahn Goldstein Group 2B Hoehn and Yahr improvement initial L-Dopa Lergotrile levodopa dosage levodopa therapy levodopa/carbidopa Lieberman Lisuride long-term treatment low doses low-dose bromocriptine mesulergine mg/day MPTP Neurol Neurology nigrostriatal number of patients on-off orthostatic hypotension Parkinson's disease parkinsonian patients patients treated patients with advanced patients with Parkinson's pergolide pharmacological postsynaptic presynaptic Rascol Raven Press Retroperitoneal fibrosis Rinne score side-effects stimulation striatal dopamine striatum Teychenne therapeutic response therapy in Parkinson's treated with bromocriptine treatment of Parkinson's Yahr stage